An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
67 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Adelaide, South Australia, Australia
Recruiting - Novartis Investigative Site
Clayton, Victoria, Australia
Recruiting
- Novartis Investigative Site
Fortaleza, Ceará, Brazil
Recruiting - Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
- Novartis Investigative Site
Vancouver, British Columbia, Canada
Recruiting - Novartis Investigative Site
Halifax, Nova Scotia, Canada
Recruiting - Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
- Novartis Investigative Site
Beijing, Chaoyang, China
Recruiting - Novartis Investigative Site
Beijing, China
Recruiting
- Novartis Investigative Site
Brno, Czechia
Recruiting - Novartis Investigative Site
Olomouc, Czechia
Recruiting - Novartis Investigative Site
Prague, Czechia
Recruiting
- Novartis Investigative Site
Nice, Alpes Maritimes, France
Recruiting - Novartis Investigative Site
Marseille, France
Recruiting - Novartis Investigative Site
Quint-Fonsegrives, France
Recruiting - Novartis Investigative Site
Suresnes, France
Recruiting
- Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany
Recruiting - Novartis Investigative Site
Hamburg, Germany
Recruiting - Novartis Investigative Site
Lübeck, Germany
Recruiting - Novartis Investigative Site
Nürtingen, Germany
Recruiting
- Novartis Investigative Site
Asti, AT, Italy
Recruiting - Novartis Investigative Site
Padova, PD, Italy
Recruiting - Novartis Investigative Site
Trento, TN, Italy
Recruiting - Novartis Investigative Site
Orbassano, TO, Italy
Recruiting - Novartis Investigative Site
Verona, VR, Italy
Recruiting
- Novartis Investigative Site
Zwolle, Overijssel, Netherlands
Recruiting - Novartis Investigative Site
Dordrecht, South Holland, Netherlands
Recruiting - Novartis Investigative Site
Hoofddorp, Netherlands
Recruiting - Novartis Investigative Site
Schiedam, Netherlands
Recruiting
- Novartis Investigative Site
Kielce, Poland
Recruiting - Novartis Investigative Site
Olsztyn, Poland
Recruiting - Novartis Investigative Site
Oświęcim, Poland
Recruiting - Novartis Investigative Site
Skorzewo, Poland
Recruiting
- Novartis Investigative Site
Singapore, Singapore
Recruiting - Novartis Investigative Site
Singapore, Singapore
Recruiting - Novartis Investigative Site
Singapore, Singapore
Recruiting
- Novartis Investigative Site
Seoul, South Korea
Recruiting - Novartis Investigative Site
Seoul, South Korea
Recruiting
- Novartis Investigative Site
Santander, Cantabria, Spain
Recruiting - Novartis Investigative Site
Badajoz, Extremadura, Spain
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Jul 2025
- Primary completion
- 29 Mar 2032
- Completion
- 19 Oct 2035
- Last update posted
- 10 Jun 2026
- Registered enrollment
- 150
- Registry id
- NCT06991556
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.